Alejandra Negro

3.6k total citations · 1 hit paper
34 papers, 863 citations indexed

About

Alejandra Negro is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alejandra Negro has authored 34 papers receiving a total of 863 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 16 papers in Hepatology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alejandra Negro's work include Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Liver Disease Diagnosis and Treatment (7 papers). Alejandra Negro is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (16 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Liver Disease Diagnosis and Treatment (7 papers). Alejandra Negro collaborates with scholars based in United States, Spain and Japan. Alejandra Negro's co-authors include Ghassan K. Abou‐Alfa, Robin Kate Kelley, Bruno Sangro, Stephen L. Chan, Philip He, Junji Furuse, Masatoshi Kudo, Yoon‐Koo Kang, Enrico N. De Toni and George Lau and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Clinical Cancer Research.

In The Last Decade

Alejandra Negro

32 papers receiving 851 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

2022 259 citations Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alejandra Negro United States	12	492	395	226	145	136	34	863
Yi‐Peng Fu China	17	389 0.8×	176 0.4×	177 0.8×	180 1.2×	43 0.3×	32	816
Silvia Bozzarelli Italy	12	281 0.6×	235 0.6×	131 0.6×	96 0.7×	102 0.8×	54	522
Fabrício Henrique Pereira De Souza United States	6	218 0.4×	648 1.6×	112 0.5×	225 1.6×	195 1.4×	8	950
Manali Bhave United States	10	160 0.3×	152 0.4×	115 0.5×	108 0.7×	31 0.2×	46	523
Emmanuel Mitry France	11	818 1.7×	511 1.3×	202 0.9×	302 2.1×	66 0.5×	22	1.2k
Shoichi Dowaki Japan	13	345 0.7×	197 0.5×	163 0.7×	361 2.5×	35 0.3×	36	710
F. De Vita Italy	11	405 0.8×	50 0.1×	196 0.9×	73 0.5×	67 0.5×	37	691
Hiroki Osumi Japan	17	600 1.2×	52 0.1×	488 2.2×	231 1.6×	216 1.6×	103	985
Jianping Wang China	17	536 1.1×	38 0.1×	198 0.9×	238 1.6×	150 1.1×	51	811

Countries citing papers authored by Alejandra Negro

Since Specialization

Citations

This map shows the geographic impact of Alejandra Negro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandra Negro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandra Negro more than expected).

Fields of papers citing papers by Alejandra Negro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandra Negro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandra Negro. The network helps show where Alejandra Negro may publish in the future.

Co-authorship network of co-authors of Alejandra Negro

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandra Negro. A scholar is included among the top collaborators of Alejandra Negro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandra Negro. Alejandra Negro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kurland, John F., Gary J. Doherty, Stephan Hois, et al.. (2025). Differential safety profiles of durvalumab monotherapy and durvalumab in combination with tremelimumab in adult patients with advanced cancers. Journal for ImmunoTherapy of Cancer. 13(5). e011140–e011140.

Kudo, Mitsuhiro, Lorenza Rimassa, Bruno Sangro, et al.. (2024). 127O Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 35. S1451–S1452. 1 indexed citations

Rimassa, Lorenza, Farshid Dayyani, Bruno Sangro, et al.. (2024). 169P Outcomes by comorbidities (CMs) with tremelimumab (T) and durvalumab (D) in the phase III HIMALAYA study in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 35. S77–S78. 1 indexed citations

Kelley, Robin Kate, Young S. Lee, James R. W. Conway, et al.. (2024). T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 42(16_suppl). 4022–4022. 1 indexed citations

Reig, María, Vincent C. Tam, Isabelle Archambeaud, et al.. (2024). 167P Non-viral aetiology subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 35. S75–S76. 1 indexed citations

Sangro, Bruno, Peter R. Galle, Robin Kate Kelley, et al.. (2024). Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma. Journal of Clinical Oncology. 42(23). 2790–2799. 20 indexed citations

He, Zhijian, Xuyang Song, Cecil Chen, et al.. (2023). Population Pharmacokinetics and Exposure–Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma. The Journal of Clinical Pharmacology. 63(11). 1221–1231. 4 indexed citations

Qin, Lei, Stephen L. Chan, Alice A. Gaughan, et al.. (2023). CO70 Matching Adjusted Indirect Comparison (MAIC) of Single Tremelimumab Regular Interval Durvalumab (STRIDE) Versus Atezolizumab with Bevacizumab (A+B) for the Treatment of Unresectable Hepatocellular Carcinoma (UHCC). Value in Health. 26(6). S27–S27. 1 indexed citations

Song, Xuyang, Robin Kate Kelley, Michelle Green, et al.. (2023). Modeling of Proliferating CD4 and CD8 T‐Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma. Clinical Pharmacology & Therapeutics. 114(4). 874–882. 2 indexed citations

10.

Song, Xuyang, Robin Kate Kelley, Anis A. Khan, et al.. (2022). Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 29(4). 754–763. 21 indexed citations

11.

Sangro, Bruno, Junji Furuse, Jung‐Won Park, et al.. (2022). 714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 33. S869–S870. 5 indexed citations

12.

Patel, Nikunj, Chad Gwaltney, Afsaneh Barzi, et al.. (2021). Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study. Quality of Life Research. 31(2). 473–485. 15 indexed citations

13.

Janjigian, Y. Y., Eric Van Cutsem, Kei Muro, et al.. (2021). P-63 MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer. Annals of Oncology. 32. S118–S118. 3 indexed citations

14.

Kelley, Robin Kate, et al.. (2020). 32P Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). Annals of Oncology. 31. S1429–S1429. 1 indexed citations

15.

Kelley, Robin Kate, Bruno Sangro, William Proctor Harris, et al.. (2020). Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology. 38(15_suppl). 4508–4508. 82 indexed citations

16.

Abou‐Alfa, Ghassan K., Stephen L. Chan, Junji Furuse, et al.. (2018). A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.. Journal of Clinical Oncology. 36(15_suppl). TPS4144–TPS4144. 78 indexed citations

17.

Negro, Alejandra, Bhawanjit K. Brar, Yusu Gu, et al.. (2006). erbB2 is required for G protein-coupled receptor signaling in the heart. Proceedings of the National Academy of Sciences. 103(43). 15889–15893. 40 indexed citations

18.

Negro, Alejandra. (2004). Essential Roles of Her2/erbB2 in Cardiac Development and Function. PubMed. 59(1). 1–12. 151 indexed citations

19.

Chantada, Guillermo, Alejandra Negro, Ernesto Gil Deza, et al.. (2004). Adherence to standard therapy for the treatment of childhood CNS tumors in Argentina. An audit perspective. Journal of Clinical Oncology. 22(14_suppl). 8573–8573.

20.

Gercovich, Felipe G., et al.. (1989). 5 fluorouracil cyclophosphamide and mitoxantrone fucimix vs fucimix prednisone pdn for advanced breast cancer abc a prospective and randomized trial preliminary report. 30. 255. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact